| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | OTU domain-containing protein 7B, Cellular zinc finger anti-NF-kappa-B protein, Zinc finger A20 domain-containing protein 1, Zinc finger protein Cezanne, OTUD7B, ZA20D1 |
| Entrez GeneID | 56957 |
| WB Predicted band size | 92.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This OTU7B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 757-784 amino acids from the C-terminal region of human OTU7B. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于OTU7B抗体的模拟参考文献示例(实际文献可能需要进一步检索验证)：
1. **文献名称**: *"OTUD7B Regulates NF-κB Signaling through Deubiquitination of TRAF3 in Innate Immunity"*
**作者**: Li, X., et al.
**摘要**: 本研究揭示了OTU7B(OTU domain-containing protein 7B)通过特异性去泛素化TRAF3调控NF-κB信号通路的分子机制。作者使用OTU7B抗体进行免疫共沉淀实验，证实其与TRAF3的相互作用，并发现OTU7B缺失会增强炎症反应。
2. **文献名称**: *"Structural and Functional Characterization of the Deubiquitinase OTU7B"*
**作者**: Zhang, Y., et al.
**摘要**: 文章解析了OTU7B的晶体结构，并通过体外酶活实验证明其对K63-linked泛素链的特异性切割作用。研究利用OTU7B抗体进行Western blot验证，发现其在多种癌细胞系中高表达，提示可能的肿瘤调控功能。
3. **文献名称**: *"Development of a Monoclonal Antibody Specific for Human OTU7B and Its Application in Clinical Samples"*
**作者**: Wang, H., et al.
**摘要**: 该研究报道了一种高特异性OTU7B单克隆抗体的开发，并通过免疫组化验证其在正常组织和肿瘤组织中的表达差异。抗体被成功应用于临床样本分析，支持OTU7B作为潜在生物标志物的可能性。
4. **文献名称**: *"OTU7B Modulates Autophagy by Stabilizing Beclin-1 through Deubiquitination"*
**作者**: Chen, L., et al.
**摘要**: 本文发现OTU7B通过去泛素化Beclin-1调控自噬过程。研究者使用OTU7B抗体进行免疫荧光共定位实验，证实其在自噬体形成中的亚细胞定位，为神经退行性疾病研究提供了新视角。
---
**注意**：以上内容为模拟示例，实际文献可能需要通过PubMed、Google Scholar等平台以关键词(如OTU7B/OTUD7B + antibody/deubiquitinase)检索。若需具体文献，建议补充基因别名(如OTUD7B)或研究领域进一步筛选。
The OTU7B antibody targets OTU deubiquitinase 7B (OTU7B), a member of the ovarian tumor protease (OTU) family of deubiquitinating enzymes (DUBs). OTU7B, also known as OTUD7B or Cezanne2. is characterized by an OTU domain that mediates its catalytic activity in hydrolyzing ubiquitin chains. It plays a regulatory role in cellular processes such as inflammation, DNA repair, and apoptosis by selectively cleaving Lys48- or Lys63-linked polyubiquitin chains from substrate proteins. OTU7B is implicated in modulating NF-κB signaling, where it deubiquitinates key components like TRAF6 or RIP1 to fine-tune immune responses. Dysregulation of OTU7B has been linked to cancers, neurodegenerative disorders, and autoimmune diseases, highlighting its therapeutic potential.
The OTU7B antibody is widely used in research to study protein expression, localization, and interactions via techniques like Western blotting, immunoprecipitation, and immunofluorescence. It has been critical in elucidating OTU7B’s role in stress response pathways and its crosstalk with other DUBs or E3 ligases. Recent studies also explore OTU7B’s involvement in viral infection responses and metabolic regulation. Commercial antibodies are typically validated for specificity against the OTU domain or unique epitopes, ensuring reliable detection in diverse experimental models. Understanding OTU7B’s mechanisms remains vital for developing targeted therapies against diseases linked to ubiquitination imbalances.
×
